The Mount Sinai School of Medicine (MSSM) Alzheimer Disease Research Center (ADRC) continues its commitment to characterize, diagnose, and treat individuals with cognitive decline and dementia. The center is committed to finding causes, treatments, and means of preventing the disease, while also minimizing the emotional and economic cost of care. MSSM ADRC is dedicated to the identification of the clinical and biological benchmarks representing clinical and molecular endophenotypes. Our goal is to provide investigators with a wide distribution of: (a) well characterized patients with AD and other dementias, (b) individuals with MCI, a possible prodromal condition to dementia, and (c) healthy elders for research studies We focus on the very elderly and minority populations, and we have planned studies to insure that they are well-represented in our research efforts. We will assist the broadest community of investigators in accessing populations for clinical investigations (including studies to develop novel biomarkers for diagnosis and disease progression) and in conducting clinical trials of new agents. We will collaborate with the Departments of Psychiatry, Neurology, and Neuroscience in order to stimulate cutting-edge science to address the etiology and pathogenesis of AD. The environment and support provided in our last funding period has resulted in actively funded research projects as well as soon to-be-submitted proposals, all of which draw upon material and expertise from the ADRC Cores. This is evidenced in the three new ADRC Projects proposed herein, all of which feature junior investigators as Project Leaders or Co-Leaders. These Projects are highly innovative and highly integrated with each other and share the endophenotyping theme. As a group, the Projects all focus on aspects of the gamma- secretase reaction, the final step in amyloid beta generation. We will provide core resources and scientific environment to insure the growth of research in AD and related disorders. We will maximize the visibility of our center and its staff and activities in order to raise awareness of the disease We propose to continue our efforts to bring new perspectives to the problem of AD by fostering the growth of new junior researchers and recruiting researchers from other specialty areas into AD-related studies.

Public Health Relevance

Alzheimer disease is a devastating disease that robs an individual of his or her intellect and social capacity. The mission of the MSSM ADRC is to understand the disease pathology so that better treatments, cures, and, ultimately, preventatives are possible.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-30
Application #
8662598
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
1997-05-01
Project End
2015-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
30
Fiscal Year
2014
Total Cost
$1,719,660
Indirect Cost
$596,070
Name
Icahn School of Medicine at Mount Sinai
Department
Psychiatry
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Bryois, Julien; Garrett, Melanie E; Song, Lingyun et al. (2018) Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. Nat Commun 9:3121
Miller, M L; Ren, Y; Szutorisz, H et al. (2018) Ventral striatal regulation of CREM mediates impulsive action and drug addiction vulnerability. Mol Psychiatry 23:1328-1335
Fazio, Leonardo; Pergola, Giulio; Papalino, Marco et al. (2018) Transcriptomic context of DRD1 is associated with prefrontal activity and behavior during working memory. Proc Natl Acad Sci U S A 115:5582-5587
Gusev, Alexander; Mancuso, Nicholas; Won, Hyejung et al. (2018) Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nat Genet 50:538-548
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Khan, Atlas; Liu, Qian; Wang, Kai (2018) iMEGES: integrated mental-disorder GEnome score by deep neural network for prioritizing the susceptibility genes for mental disorders in personal genomes. BMC Bioinformatics 19:501
Wang, Jen-Chyong; Alinaghi, Somayeh; Tafakhori, Abbas et al. (2018) Genetic screening in two Iranian families with early-onset Alzheimer's disease identified a novel PSEN1 mutation. Neurobiol Aging 62:244.e15-244.e17
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325

Showing the most recent 10 out of 555 publications